Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer
Authors
Keywords
-
Journal
Biomedicines
Volume 10, Issue 5, Pages 1047
Publisher
MDPI AG
Online
2022-05-01
DOI
10.3390/biomedicines10051047
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
- (2022) An-Ping Shi et al. Frontiers in Immunology
- Global Patterns and Trends in Lung Cancer Incidence: A Population-Based Study
- (2021) Yanting Zhang et al. Journal of Thoracic Oncology
- Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients
- (2021) Karla Montalbán-Hernández et al. Cancers
- The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
- (2020) Quentin Lecocq et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis
- (2019) Yanfang Wang et al. Cancer Cell International
- Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.
- (2019) Ila J Datar et al. CLINICAL CANCER RESEARCH
- Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
- (2019) Alexander Haragan et al. LUNG CANCER
- A robust gene signature for the prediction of early relapse in stage I-III colon cancer
- (2018) Weixing Dai et al. Molecular Oncology
- Managing Patients With Relapsed Small-Cell Lung Cancer
- (2018) Jun Gong et al. Journal of Oncology Practice
- Soluble immune checkpoints in cancer: production, function and biological significance
- (2018) Daqian Gu et al. Journal for ImmunoTherapy of Cancer
- LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
- (2017) Yayi He et al. Journal of Thoracic Oncology
- Non–Small Cell Lung Cancer
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
- (2016) Roberto Tinoco et al. IMMUNITY
- PD-L1 Expression in Lung Cancer
- (2016) Hui Yu et al. Journal of Thoracic Oncology
- Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells
- (2016) Maurizio Perdicchio et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity
- (2016) Marion Pepin et al. Scientific Reports
- Lung cancer: Biology and treatment options
- (2015) Hassan Lemjabbar-Alaoui et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lectin Galactoside-binding Soluble 3 Binding Protein (LGALS3BP) Is a Tumor-associated Immunomodulatory Ligand for CD33-related Siglecs
- (2014) Heinz Läubli et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A nineteen gene-based risk score classifier predicts prognosis of colorectal cancer patients
- (2014) Seon-Kyu Kim et al. Molecular Oncology
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
- (2013) Charles G. Drake et al. Nature Reviews Clinical Oncology
- A Risk Model for Lung Cancer Incidence
- (2012) C. Hoggart et al. Cancer Prevention Research
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
- (2011) Roy S Herbst et al. LANCET
- Lung cancer screening
- (2010) U Pastorino BRITISH JOURNAL OF CANCER
- Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?
- (2010) J. Subramanian et al. JNCI-Journal of the National Cancer Institute
- A Clinical Model to Estimate Recurrence Risk in Resected Stage I Non-Small Cell Lung Cancer
- (2009) Boone Goodgame et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Potent Phagocytic Activity with Impaired Antigen Presentation Identifying Lipopolysaccharide-Tolerant Human Monocytes: Demonstration in Isolated Monocytes from Cystic Fibrosis Patients
- (2009) Carlos del Fresno et al. JOURNAL OF IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now